TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
TCL Archive Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial December 25, 2009
TCL Archive EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure. March 2, 2007